ORBi: Baron Frédéric - Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.

Reference : Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin th...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Hematology
	To cite this reference:	http://hdl.handle.net/2268/6289

Title :	Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.
Language :	English
Author, co-author :	Baron, Frédéric [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
	Frere, Pascale [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
	Fillet, Georges [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
	Beguin, Yves [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Publication date :	2003
Journal title :	British Journal of Haematology
Publisher :	Blackwell Publishing
Volume :	123
Issue/season :	1
Pages :	103-5
Audience :	International
ISSN :	0007-1048
e-ISSN :	1365-2141
City :	Oxford
Country :	United Kingdom
Keywords :	[en] Adult ; Blood Transfusion ; Drug Administration Schedule ; Erythropoietin, Recombinant/administration & dosage/therapeutic use ; Female ; Hemoglobins/analysis ; Humans ; Male ; Middle Aged ; Multiple Myeloma/blood/drug therapy/surgery ; Peripheral Blood Stem Cell Transplantation ; Reoperation ; Transplantation, Autologous
Abstract :	[en] We evaluated the ability of recombinant human erythropoietin (rHuEpo) therapy, given before high-dose therapy (HDT), to allow autologous peripheral blood stem cell transplantation (PBSCT) without red blood cell (RBC) transfusions. Eleven multiple myeloma patients underwent tandem HDT and autologous PBSC, receiving 500 U/kg/week rHuEpo from d 30 after initial transplant. Haemoglobin levels were 9.5 +/- 1.1 g/dl and 12.5 +/- 0.9 g/dl at the first and second transplant respectively (P < 0.001). RBC transfusions were required for 10/11 patients for the first transplant versus 1/11 for the second (P < 0.001). To conclude, a short course of rHuEpo therapy before HDT facilitates the performance of an autologous transplant without RBC transfusions.
Permalink :	http://hdl.handle.net/2268/6289

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	Epo-rHuEpo-BMT auto x 2 myeloma.BJH.pdf		Publisher postprint	125.85 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5